Health
CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine – GlobeNewswire
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection …
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection
Supports the Development of New Approaches to Treat Multiple Neurological Diseases
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) — CytoDel, Inc. (CytoDel or the Company), a privately-held corporation, today announces the publication of preclinical data on the Companys lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine….
-
General14 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News20 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business22 hours agoBell Potter names the best ASX shares to buy in October
-
General19 hours agoAustralia welcomes Gaza peace progress, hostage release